Spire Wealth Management’s Cartesian Therapeutics RNAC Stock Holding History

Spire Wealth Management’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-50	Closed	-$511	–	2450
2025 Q3	$511	Hold	50	–	–	﹤0.01%	2353
2025 Q2	$520	Hold	50	–	–	﹤0.01%	2365
2025 Q1	$659	Hold	50	–	–	﹤0.01%	2440
2024 Q4	$896	Buy	+50	New	+$1.01K	﹤0.01%	2388
2022 Q4	–	Sell	-100	Closed	-$5K	–	2387
2022 Q3	$5K	Hold	100	–	–	﹤0.01%	1758
2022 Q2	$4K	Hold	100	–	–	﹤0.01%	2214
2022 Q1	$4K	Hold	100	–	–	﹤0.01%	2295
2021 Q4	$10K	Hold	100	–	–	﹤0.01%	2393
2021 Q3	$12K	Hold	100	–	–	﹤0.01%	2053
2021 Q2	$13K	Hold	100	–	–	﹤0.01%	2039
2021 Q1	$14K	Buy	+100	New	+$12.4K	﹤0.01%	2307

Other funds holding RNAC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Spire Wealth Management's RNAC Position: Q4 2025 in Review

Spire Wealth Management sold out of Cartesian Therapeutics (RNAC) in Q4 2025, closing a stake of 50 shares — an estimated $511 sold.

Spire Wealth Management first reported a position in RNAC in Q1 2021 and held it in 11 quarters. The position peaked at $14K in Q1 2021. 67 funds tracked by Wall St. Rank hold RNAC as of Q4 2025.

Spire Wealth Management reported no remaining Cartesian Therapeutics position as of Q4 2025 after selling out during the quarter.
Spire Wealth Management sold 50 Cartesian Therapeutics shares in Q4 2025, an estimated $511.
Spire Wealth Management first reported a position in Cartesian Therapeutics in Q1 2021 and held it in 11 quarters.
Spire Wealth Management's Cartesian Therapeutics position peaked at $14K in Q1 2021.
67 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2025.

Based on Spire Wealth Management's 13F filing for Q4 2025, filed 14 Jan 2026.